SERB Pharmaceuticals in den Nachrichten
Globaler Anbieter seltener Medikamente
Tamtam hat 17 aktuelle Artikel über SERB Pharmaceuticals gefunden.
- SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
- Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
- SERB Sizes Up €1bn Sales With M&A Savoir Faire
- Hansa licenses Idefirix to SERB for $133m
- Mayer Brown advises SERB Pharmaceuticals on the agreement entered into with Hansa Biopharma AB to acquire European and MENA rights to Idefirix®(imlifidase)
- Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
- Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
- SERB signs agreement to acquire Idefirix rights for $133.6m
- SERB Pharmaceuticals buys European and MENA rights to kidney transplant drug Idefirix for €115M
- SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
- Hansa Biopharma Signs €115 Million Imlifidase Licensing Agreement with SERB
- SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
- SERB Pharma to acquire European and MENA rights to Idefirix from Hansa
- SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
- Dr Vignesh Rajah
- SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million
- Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie SERB Pharmaceuticals?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden